Stevanato Group to Present at Upcoming Investor Conferences

STVN 11.11.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:UBS Global Healthcare Conference
Date of Upcoming Event:2024-11-19
Name of Upcoming Event:Jefferies London Healthcare Conference
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Citi 2024 Global Healthcare Conference
Full Press ReleaseSEC FilingsOur STVN Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - Stevanato Group to Present at Upcoming Investor Conference
  • 11.11.2024 - Stevanato Group to Present at Upcoming Investor Conferences
  • 11.05.2024 - Stevanato Group Reports Financial Results for the Third Quarter of 2024

Recent Filings

  • 01.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors

Stevanato Group to Present at Upcoming Investor Conferences

November 11, 2024 6:32am ESTDownload as PDF

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences.

The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, November 12, 2024 at 11:00 a.m. (PT). The Company will also present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:00 a.m. (GMT), and the Citi 2024 Global Healthcare Conference in Miami on Tuesday, December 3, 2024 at 1:45 p.m. (ET). A live webcast of each event will be available on the Company’s website atwww.stevanatogroup.comunder the "Investors" section. Replays of the webcasts will be available for approximately 90 days after each event.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit:www.stevanatogroup.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241111945147/en/

MediaStevanato Groupmedia@stevanatogroup.com

Investor RelationsLisa Mileslisa.miles@stevanatogroup.com

Source: Stevanato Group

Released November 11, 2024

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com